Breaking News

Metrics Founder Retires

November 12, 2013

Hodges to pursue other interests


Metrics
president and founder, Phil Hodges, will retire after 19 years with the company. The company opened in 1994 as a small contract analytical lab with four employees and has since grown to more than 300. The company now offers first-time-in-man development, Phase I, II and III clinical trial materials, as well as full analytical methods development and validation from its custom-built 100,000 sq.-ft. facility in Greenville, NC, which includes a highly potent products containment suite. Last year, Metrics was acquired by Mayne Pharma, a pharmaceutical company based in Melbourne, Australia.

“I built this business and I am proud of it,” said Mr. Hodges, “And that’s what I loved about the Mayne deal, they really got it, they understood what we are doing here. But I’ll be honest, after 19 years, I’m ready to get out of day-today operations and go do something different.” Mr. Hodges will continue to serve on the board of directors at Mayne Pharma.

Related Contract Manufacturing:

Related Compliance:

blog comments powered by Disqus
  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important

  • A Case for One Assay Analysis of PK and Immunogenicity in Biosimilar Research

    A Case for One Assay Analysis of PK and Immunogenicity in Biosimilar Research

    Stephanie Mowery, Sherri Rinker, Franklin Spriggs and Bo Kowalcyk , AIT Bioscience||June 2, 2015
    Moving forward clinical studies will have to include a comparative assessment of pharmacokinetics and immunogenicity to the original reference biologic drug

  • Growth Prospects for Pharmaceutical Contract Packaging

    Growth Prospects for Pharmaceutical Contract Packaging

    Walt Berghahn , Healthcare Compliance Packaging Council (HCPC)||June 2, 2015
    Spurred by several trends including the patent cliff, new product launches and changes in healthcare, the contract packaging market is looking at sustained growth in the years ahead